An update from Medistim ASA ( (DE:MD1) ) is now available.
Medistim ASA has strengthened its commercial operations by appointing Mr. Mike Karim as Chief Commercial Officer, bringing extensive industry expertise and leadership experience from notable companies in the cardiac and vascular fields. The company has also appointed Mr. Tony Winter to lead its AMERICAS sales region, aiming to drive expansion in the USA, its largest current market. These strategic moves are expected to support Medistim’s growth strategy for 2025, focusing on the launch of the INTUI software platform and advancing innovation in the cardiac and vascular segments.
More about Medistim ASA
Medistim ASA, based in Oslo, Norway, is a leader in the niche market of ultrasound technology. The company develops and commercializes medical equipment for cardiac, vascular, and transplant surgeries. Established in 1984, Medistim has a history of profitable growth and invests in new product development. It operates with wholly owned subsidiaries in several countries, including the USA, Canada, and China, and has over 60 distributors worldwide.
YTD Price Performance: 3.17%
Average Trading Volume: 230
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €245.3M
Find detailed analytics on MD1 stock on TipRanks’ Stock Analysis page.